The relationship between cholesterol and cognitive function is homocysteine-dependent by Cheng, Yibin et al.
© 2014 Cheng et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Clinical Interventions in Aging 2014:9 1823–1829
Clinical Interventions in Aging Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1823
O r I g I n A l  r e s e A r C h
open access to scientific and medical research

















1Institute for environmental health 
and related Product safety, Chinese 
Center for Disease Control and 
Prevention, Beijing, People’s republic 
of China; 2Department of Psychiatry, 
3Department of Biostatistics, 
4Department of neurology, Indiana 
University school of Medicine, 
Indianapolis, Indiana, UsA; 5eli lilly  
and Company, Indianapolis, 
Indiana, UsA; 6shandong Institute 
for Prevention and Treatment of 
endemic Disease in China, Jinan, 
People’s republic of China; 7sichuan 
Provincial Center for Disease 
Control and Prevention in China, 
Chengdu, People’s republic of 
China; 8Department of Pathology 
and laboratory Medicine, Indiana 
University school of Medicine, 
9Indiana University Center for Aging 
research, 10regenstrief Institute, Inc., 
Indianapolis, Indiana, UsA
Correspondence: sujuan gao
Department of Biostatistics, Indiana 
University school of Medicine, 410 West 
10th street, #3,000, Indianapolis,  
In 46202-2872, UsA
email sgao@iupui.edu 
Introduction: Previous studies have identified hyperlipidemia as a potential risk factor for 
dementia and Alzheimer’s disease. However, studies on cholesterol measured in late-life and 
cognitive function have been inconsistent. Few studies have explored nonlinear relationships 
or considered interactions with other biomarker measures.
Methods: A cross-sectional sample of 1,889 participants from four rural counties in the 
People’s Republic of China was included in this analysis. Serum total cholesterol, high-density 
lipoprotein, triglycerides, and homocysteine levels were measured in fasting blood samples. 
A composite cognitive score was derived based on nine standardized cognitive test scores. 
Analysis of covariance models were used to investigate the association between biomarker 
measures and the composite cognitive scores.
Results: There was a significant interaction between the homocysteine quartile group and the 
cholesterol quartile group on cognitive scores (P=0.0478). In participants with normal homo-
cysteine levels, an inverse U-shaped relationship between total cholesterol level and cognitive 
score was found, indicating that both low and high cholesterol levels were associated with 
lower cognitive scores. In participants with high homocysteine levels, no significant association 
between cholesterol and cognition was found.
Conclusion: The relationship between cholesterol levels and cognitive function depends upon 
homocysteine levels, suggesting an interactive role between cholesterol and homocysteine 
on cognitive function in the elderly population. Additional research is required to confirm 
our findings in other populations, and to explore potential mechanisms underlying the lipid–
homocysteine interaction. 
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Introduction
With the increasing public health challenge of dementia and cognitive impairment 
throughout the world, the identification of a modifiable risk factor would be critical 
in the prevention of dementia.1 Previous studies have indicated that hyperlipidemia 
may be a risk factor for dementia and Alzheimer’s disease (AD).2–4 However, although 
earlier results suggested a link between high midlife cholesterol levels and increased 
dementia risk,5–8 later studies found no association between midlife cholesterol 
and subsequent dementia.9–12 In addition, studies on late-life cholesterol levels con-
flicted with some studies reporting that low late-life cholesterol was associated with 
increased dementia risk, although others found no association.2,13,14
One potential explanation for the inconsistencies in the relationship between cho-
lesterol and cognitive function is that it may be due to a confounding treatment effect. 
Most previous studies were from developed countries in which individuals with high 
cholesterol levels had been aggressively treated with lipid-lowering medications, some of 
which have been shown to be potentially protective of dementia risk.3 Thus, cholesterol 
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levels, particularly those measured in late-life, may reflect a 
combination of the detrimental effect of high cholesterol and 
the protective effect of lipid-lowering medications, making 
it more difficult to untangle the two opposite effects in such 
populations. Another potential explanation for the conflicting 
results on cholesterol and cognition is the failure to control for 
other relevant risk factors. One recent meta-analysis based on 
cohort studies found that higher levels of homocysteine were 
associated with increased dementia risk,15 but no studies to 
date have considered potential interactions between choles-
terol and homocysteine on cognitive function. We hypothesize 
that a clear relationship between cholesterol and cognitive 
function may be observed in populations in which few indi-
viduals take cholesterol-lowering medications and in which 
other biomarkers are measured. In this article, we report results 
from a cross-sectional study of cholesterol, homocysteine, and 
cognitive function in a rural, elderly Chinese cohort. 
Methods
study population
Participants for this study were recruited on two occasions. 
Between December 2003 and May 2005, 2,000 individuals 
aged 65 years and over from four counties in the People’s 
Republic of China were enrolled. Two counties were from 
Sichuan province in southwestern People’s Republic of China 
and the other two counties were from Shandong province in 
eastern People’s Republic of China. Cognitive assessment 
was conducted at baseline, and at 2.5 years and 7 years 
after baseline. Of the 2,000 participants enrolled during 
2003–2005, 1,248 were reevaluated during 2010–2012. 
A second enrollment was conducted between 2010 and 
2012, approximately 7 years after the baseline study was 
conducted. Individuals from the four original study sites who 
had since turned 65 years old, and who were not enrolled in the 
original cohort, were invited to participate in the study. Eight-
hundred-and-eight individuals were enrolled during the second 
enrollment wave; thus 2,056 participants underwent cognitive 
assessment during 2010–2012. This article reports the analysis 
of the data obtained during the 2010–2012 evaluation. The 
study was approved by the Indiana University (IU) Institutional 
Review Board and the Institute for Environmental Health and 
Related Safety, Chinese Center for Disease Control and Pre-
vention. Details of the study were described previously.16 
Biomarker measures
Blood samples were collected during the 2010–2012 evalu-
ation. Of 2,056 individuals evaluated with the cognitive 
 assessment, 1,889 (91.9%) consented to blood sample 
 collection. Fasting blood samples were collected in the morn-
ing using 10 mL purple top (containing ethylenediaminetetra-
acetic acid) Vacutainer® tubes manufactured in the United 
States. Serum homocysteine, triglycerides, low-density 
lipoprotein (LDL), and high-density lipoprotein (HDL) 
were measured using Roche Diagnostic kits and a Hitachi 
Automatic Biochemistry Analyzer 9700. Total cholesterol 
levels were calculated using the sum of the LDL and HDL 
plus one-fifth of triglyceride levels. APOE genotype was 
determined by the multiplex tetra-primer amplification refrac-
tory mutation system polymerase chain reactions.17
Cognitive assessment
Cognitive assessment was conducted in face-to-face inter-
views using nine cognitive tests: the Community Screening 
Instrument for Dementia (CSID); the Consortium to Establish 
a Registry for Alzheimer’s Disease (CERAD) ten-word list 
learning; word list recall;18 IU Story Recall;19 Animal Fluency 
test;20 Boston Naming Test;21 Stick Design; Delayed Stick 
Design;22 and the IU Token test.23,24 The CSID was developed 
as a screening tool for dementia in populations with various 
cultural backgrounds and literacy levels. Details of the 
instrument have been published elsewhere.25 The CSID cog-
nitive assessment items measure the following functions in a 
short interview with the study participants: memory; abstract 
thinking; judgment; and other disturbances of higher corti-
cal function (aphasia, apraxia, agnosia, and constructional 
difficulty). The CSID has demonstrated both good 2-week 
test–retest reliability and interrater reliability, in addition to 
good validity in detecting dementia in various populations.25,26 
CSID has 30 items and scores range from 0–30. 
The CERAD Word List Learning test is one of the 
measures from the CERAD neuropsychological assessment 
battery, which was designed to assess cognitive skills in the 
elderly.18 It consists of a ten-item, three-trial word list in 
which free recall is taken after each learning trial and after 
a brief delay (approximately 5 minutes). The score is the 
total number of words recalled across the three learning trials 
(range: 0–30) and at delay (range: 0–10). The IU Story Recall 
task19 was created by the research team to be suitable to the 
Chinese culture and the rural population. The examiner reads 
the story out loud to the subject, who then attempts to recall 
the story verbatim. The story has 14 units of information that 
are gist scored (range: 0–14), meaning a recalled answer is 
deemed correct if the main point is recalled, in contrast to 
verbatim. The story was tested in 1,500 elderly Chinese adults 
in a previous pilot study and was found to be acceptable to 
the villagers; it produced a normally distributed range of 
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scores.27 The Animal Fluency test is a measure of executive 
function in which a subject names as many animals as pos-
sible in 60 seconds.20 The IU Token test is a brief measure 
of language comprehension and working memory (12 items; 
range: 0–24).23 The validity of the CSID, CERAD Word 
List Learning and recall, and the Animal Fluency test have 
been previously established in the Chinese population and 
elsewhere.28 In this analysis, a standardized score for each 
cognitive test was created by subtracting the sample mean 
and dividing it by the sample standard deviation (SD). A 
composite cognitive Z-score was derived using the average 
of standardized scores of the nine cognitive tests.
Other information
Other information collected during the interview included 
age, sex, whether the participant attended school and years 
of schooling, marital status, household composition, alcohol 
consumption and smoking history, as well as a history of 
cancer, Parkinson’s disease, diabetes, hypertension, stroke, 
heart attack, head injury, and bone fracture. For each reported 
medical condition, participants were also asked whether they 
were taking medications for the condition. None of the par-
ticipants reported hyperlipidemia, and none reported taking 
medication for this condition. Participants’ height, weight, 
and blood pressure (measured twice) were measured during 
the interview. Body mass index (BMI) was derived from 
height and weight measurements. The average of the two 
blood pressure measures were used in our analyses.
statistical analysis
Univariate analysis of covariance (ANCOVA) models using 
the composite cognitive Z-score as the dependent variable 
and each participant’s characteristics as the independent 
variables were used to select potential covariates associated 
with cognitive score. To detect potential nonlinear relation-
ships between biomarker measures and cognitive scores, 
we divided biomarker values into quartile groups and used 
quartile groups in both univariate and multivariate ANCOVA 
models. We also examined interactions among significant 
markers in multivariate models and conducted a stratified 
analysis when significant interactions were detected. In addi-
tion, we explored potential interactions between APOEe4 
carrier status and each of the biomarkers. 
Results
Participants (n=2,055) completed the cognitive assessment 
during the 2010–2012 evaluation. This analysis included 
1,889 participants with both biomarker measures and 
cognitive test scores. In Table 1, we present data on the 
patients’ demographic characteristics and on the medical his-
tory of the participants. The mean age (SD) of the participants 
in the analysis was 73.5 years (5.9 years), with 53.9% being 
female. The average number of years (SD) of education was 
low at 2.4 years (3.0 years), and the average BMI (SD) was 
23.1 (3.8), which was within the normal weight range.
In Table 2, we present summary data on the cognitive 
tests in calculating the composite Z-score. In Table 3, we 
present the summary data of biomarker measures. Approxi-
mately one-half of the participants (the first [Q1] and second 
[Q2] quartile groups) had homocysteine levels in the normal 
range (14 μmol/L), and three-quarters of the participants 
(the first three quartile groups, Q1–Q3) had cholesterol lev-
els in the normal range (200 mg/dL). Of all biomarkers 
considered in univariate models, total cholesterol, LDL, and 
homocysteine levels were significantly related to composite 
cognitive scores (P0.0001). HDL, triglyceride, glucose, or 
APOE status were not significantly associated with cogni-
tive function. Since LDL and total cholesterol were highly 
correlated, we concentrated on describing the results using 
cholesterol quartile groups in the final multivariate models. 
Results for LDL were similar. In the multivariate model 
adjusting for age, sex, years of education, BMI, smoking, and 
history of heart disease, we found a significant interaction 
Table 1 Demographic characteristics of the study population 
(n=1,889)
Participant characteristics Mean or N SD or %
Age (years) 73.45 5.93
Female (%) 1,017 53.9
Years of education 2.39 3.00
Body mass index (kg/m2) 23.08 3.77
systolic blood pressure 152.21 27.87
Diastolic blood pressure 86.18 12.83
Consume alcohol (%) 725 38.4
smoker (%) 750 39.7






heart disease 277 14.7
Arthritis 223 11.8
Thyroid disease 12 0.6
Kidney disease 34 1.8
liver disease 19 1.0
Cancer 21 1.1
head injury 71 3.8
Fracture 167 8.9
Abbreviations: n, number of participants; sD, standard deviation.





between the homocysteine quartile group and the cholesterol 
quartile group (P=0.0478), indicating that the association 
between cholesterol levels and cognitive scores depends on 
homocysteine levels.
In Table 4, we present ANCOVA models for the relation-
ship between cholesterol levels and cognitive scores strati-
fied by homocysteine quartile groups, while adjusting for 
other covariates. An inverse U-shaped relationship between 
cholesterol level and cognitive scores was observed in the 
group with the lowest homocysteine level. Using the highest 
cholesterol group as the reference, participants in the lowest 
cholesterol group had significantly lower cognitive scores 
(P=0.0166), and those in the third cholesterol quartile group 
(Q3) had significantly higher cognitive scores (P=0.0148) 
than those in the reference group. It is worth noting that 
participants in the Q3 group with cholesterol levels ranging 
from 154.6–186.7 mg/dL had the highest cognitive scores. 
For participants in the middle two homocysteine quartile 
groups (Q2 and Q3) with levels from 11.82 μmol/L to 
20.12 μmol/L, those with the lowest cholesterol levels had 
significantly lower cognitive scores than the highest cho-
lesterol group. For participants in the highest homocysteine 
group (Q1), however, there was no significant association 
between cholesterol and cognitive scores. Figure 1 displays 
predicted mean cognitive Z-scores in the four cholesterol 
groups stratified by homocysteine quartile groups. A curvi-
linear relationship between cholesterol and cognitive score 
can be observed in the first homocysteine quartile group, but 
not in the other homocysteine groups.
There were 804 participants with homocysteine in the 
normal range (14 μmol/L).29 A similar inverse U-shape was 
detected when we fitted another ANCOVA model that was 
restricted to these participants with normal homocysteine. To 
ensure that significant associations found in this analysis were 
not due to poor nutritional status of participants with prevalent 
dementia or cognitive impairment, we repeated the multivariate 
ANCOVA models shown in Table 3 by excluding participants 
in the bottom 10% of the composite cognitive Z-scores. Results 
were similar to those obtained using the entire sample.
Discussion
In this rural elderly Chinese population, we found that the 
relationship between cholesterol levels and cognitive func-
tion is homocysteine-dependent. In participants with normal 
homocysteine levels, an inverse U-shaped relationship 
between total cholesterol levels and cognitive score was 
found indicating that both low and high cholesterol levels 
Table 2 summary of cognitive functions measured in the study 
population (n=1,889)
Cognitive functions Summary measures
Mean SD Min Median Max
CsID test 25.84 3.54 6.00 27.00 30.00
IU story recall test 5.06 3.13 0.00 5.00 14.00
Animal Fluency test 13.36 4.93 0.00 13.00 32.00
CerAD Word listing  
learning test
13.24 4.46 0.00 13.00 29.00
CerAD Word listing  
recall test
4.45 2.30 0.00 5.00 10.00
IU Token test 16.66 5.26 0.00 18.00 24.00
Boston naming test 13.73 3.54 0.00 14.00 20.00
stick Design test 10.40 2.54 0.00 12.00 12.00
Delayed stick Design  
test
5.01 2.69 0.00 5.00 12.00
Abbreviations: n, number of participants; sD, standard deviation; Min, minimum; 
Max, maximum; CsID, Community screening Instrument for Dementia; IU, Indiana 
University; CerAD, the Consortium to establish a registry for Alzheimer’s Disease.
Table 3 summary of biomarker measures (n=1,889)
Biomarker Mean SD Median Interquartile range
Total cholesterol level (mg/dl) 158.9 47.1 154.3 (125.3, 186.7)
hDl (mg/dl) 49.3 17.7 46.0 (37.1, 58)
lDl (mg/dl) 91.1 35.2 88.9 (65.0, 112.1)
Triglycerides (mg/dl) 40.6 32.1 32.9 (22.8, 48.3)
homocysteine (μmol/l) 17.2 8.4 15.3 (11.8, 20.1)
glucose (mg/dl) 85.9 30.3 79.3 (69.7, 92.1)
Cholesterol quartile groups
Q1 (125.26 mg/dl) 104.3 16.0 106.7
Q2 (125.26, 154.25 mg/dl) 140.1 8.4 139.6
Q3 (154.25, 186.73 mg/dl) 170.0 9.5 170.1
Q4 (186.73 mg/dl) 222.4 30.4 214.9
homocysteine quartile groups
Q1 (11.81 μmol/l) 9.4 1.9 9.8
Q2 (11.81, 15.25 μmol/l) 13.5 0.9 13.4
Q3 (15.25, 20.12 μmol/l) 17.5 1.4 17.4
Q4 (20.12 μmol/l) 28.5 8.5 25.9
Abbreviations: n, number of participants; sD, standard deviation; hDl, high-density lipoprotein; lDl, low-density lipoprotein; Q, quartile group.
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were associated with lower cognitive scores. Our results sug-
gest that as far as cognitive function is concerned, the optimal 
cholesterol level for individuals with normal homocysteine 
levels was centered at 170 mg/dL, below the standard 
treatment cutoff point of 200 mg/dL for hyperlipidemia. In 
participants with high homocysteine levels, no significant 
association between cholesterol and cognition was found.
Few previous studies on the association between choles-
terol levels and cognitive scores included both cholesterol 
and homocysteine in identical models, or considered nonlin-
ear trends. No studies to date have explored the interaction 
between these two vascular risk markers. Of the studies 
focusing on cholesterol alone, conflicting results have been 
reported on the relationship between cholesterol, dementia, 
and cognition.3,4 In studies measuring cholesterol in those aged 
65 years or older, high cholesterol levels were reported to be 
associated with AD30,31 or cognitive impairment.32 However, 
others found that low cholesterol levels were associated with 
AD,33 dementia,14,34 or cognitive decline,35 although some 
studies reported no association between cholesterol levels 
and dementia risk.12,36 The inconsistency in results was often 
 attributed to the age-related cholesterol decline.9 However, 
unless it can be shown that the age-related decline in choles-
terol differentiates between those with cognitive impairment 
and those with normal cognition, age-related decline in cho-
lesterol cannot explain the observed discrepancy in results.
Another less often mentioned contributing factor to the 
inconsistency in results may be the confounding effect of 
statins and other lipid-lowering medications widely used in 
the elderly population. Given the potential protective effects 
of some lipid-lowering medications on cognition,3 analysis 
without the appropriate adjustment to medications may 
fail to detect meaningful associations between cholesterol 
levels and cognitive function. In this Chinese cohort, few 
participants took regular medications; therefore, the mea-
sured cholesterol levels were probably not associated with 
the confounding effects from lipid medications.
Most previous studies focused on a linear relationship 
between cholesterol levels and cognitive function, and many 
did not consider other potential biomarkers. Our results sug-
gest a more complex relationship between cholesterol and 
cognition that is homocysteine-dependent. In participants with 
Table 4 results of AnCOVA models with composite cognitive scores as the outcome variable, cholesterol Qs as independent 
variables stratified by homocysteinea
Homocysteine Cholesterol Total cohort (N=1,889) Sub-sample (N=1,700)b
Estimation SE P-value Estimation SE P-value
Q1 (11.81 μmol/l) Q1 (125.26 mg/dl) -0.18 0.08 0.0208* -0.19 0.07 0.0063*
Q2 (125.26, 154.25 mg/dl) -0.08 0.08 0.3078 -0.03 0.07 0.6506
Q3 (154.25, 186.73 mg/dl) 0.20 0.08 0.0146* 0.15 0.07 0.0342
Q4 (186.73 mg/dl) reference – – reference – –
Q2 (11.81, 15.25 μmol/l) Q1 (125.26 mg/dl) -0.16 0.08 0.0355* -0.10 0.07 0.1342
Q2 (125.26, 154.25 mg/dl) -0.15 0.08 0.0506 -0.07 0.07 0.2960
Q3 (154.25, 186.73 mg/dl) 0.01 0.08 0.8820 0.06 0.07 0.3653
Q4 (186.73 mg/dl) reference – – reference – –
Q3 (15.25, 20.12 μmol/l) Q1 (125.26 mg/dl) -0.22 0.08 0.0063* -0.23 0.07 0.0017*
Q2 (125.26, 154.25 mg/dl) -0.06 0.07 0.4055 -0.13 0.07 0.0490
Q3 (154.25, 186.73 mg/dl) 0.00 0.07 0.9613 -0.05 0.07 0.4076
Q4 (186.73 mg/dl) reference – – reference – –
Q4 (20.12 μmol/l) Q1 (125.26 mg/dl) -0.06 0.08 0.4372 -0.05 0.07 0.4335
Q2 (125.26, 154.25 mg/dl) 0.06 0.09 0.5061 0.00 0.07 0.9747
Q3 (154.25, 186.73 mg/dl) -0.05 0.08 0.5209 -0.02 0.06 0.7252
Q4 (186.73 mg/dl) reference – – reference – –
normal homocysteine  
(14 μmol/l)
Q1 (125.26 mg/dl) -0.17 0.06 0.0050 -0.14 0.05 0.0103
Q2 (125.26, 154.25 mg/dl) -0.09 0.06 0.1219 -0.02 0.05 0.6965
Q3 (154.25, 186.73 mg/dl) 0.12 0.06 0.0411 0.12 0.05 0.0220
Q4 (186.73 mg/dl) reference – – reference – –
Notes: aAll models were adjusted for age, sex, years of education, smoking status, body mass index, and history of heart disease. bexcluding participants in the bottom 10% 
of composite cognitive scores. *Statistically significant values.
Abbreviations: AnCOVA, analysis of covariance; n, number of participants; Q, quartile group; se, standard error.





normal homocysteine levels, both low and high cholesterol 
levels may be detrimental to cognitive health. In addition, our 
models indicated that optimal cognitive scores are achieved 
with cholesterol levels centered at 170 mg/dL for participants 
with normal homocysteine. However, in those with high 
homocysteine, the effect of high homocysteine on cognition 
was overwhelming regardless of cholesterol levels.
There are several plausible mechanisms that may underlie 
a homocysteine-dependent relationship between cholesterol 
and cognitive function. In animal studies, increased homo-
cysteine in the diet enhanced cortex blood–brain barrier leak-
age, which could contribute to the deterioration of cognitive 
function.37 High levels of homocysteine have been associated 
with increased risk for both cardiovascular disease and all-
cause mortality,38,39 but the association between homocysteine 
and dementia or cognitive decline has not been consistently 
shown.40 Animal, cellular, and autopsy studies have con-
cluded that cholesterol plays an important role in brain func-
tion through synapse formation, membrane organization, 
amyloid-β production and deposition, and inflammation; thus, 
it is essential to maintain a certain cholesterol level for normal 
functioning.3 Under normal homocysteine levels, where the 
blood–brain barrier is intact, cholesterol levels are maintained 
to achieve optimal  cognitive function. Further, studies on car-
diovascular disease risk have found a homocysteine and lipid 
interaction showing that higher homocysteine levels increased 
disease risk regardless of lipid levels; however, a low level of 
plasma cholesterol did not seem to confer protection against 
the risk associated with increased plasma homocysteine.41 
Our study has many strengths. The study cohort was 
relatively large, allowing for the investigation of potential 
interactions among biomarker measures. A comprehensive 
set of cognitive measures was used in our study, ensuring 
robust results in grouping participants according to their 
composite cognitive scores. The cohort was unusual because 
few studies with cognitive and biomarker measures have been 
conducted in rural elderly Chinese populations. 
Finally, this study has important limitations. Our analysis 
is a cross-sectional study, and thus the observed association 
could be subject to reverse causation. However, similar 
results were found after we excluded participants with the 
worst cognitive scores, which indicates that reverse causa-
tion is unlikely. Nevertheless, longitudinal studies will be 
valuable to confirm our results, and may lead to potential 
interventions for cognitive impairment because both 
cholesterol and homocysteine can be effectively controlled 
by current medications. Another potential limitation is that 
our study was conducted in a population with a low level of 
education and with average BMI scores. It remains to be seen 
whether our results can be confirmed in other populations. 
Conclusion
In conclusion, we found that the relationship between choles-
terol levels and cognitive function depends on homocysteine 
levels, which suggests an interactive role between cholesterol 
and homocysteine in cognitive function in the elderly popu-
lation. Further research is required to confirm our findings 
in other populations and to explore potential mechanisms 
underlying the lipid–homocysteine interaction. 
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